BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 14704831)

  • 1. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition.
    Penketh PG; Shyam K; Baumann RP; Remack JS; Brent TP; Sartorelli AC
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):279-87. PubMed ID: 14704831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity.
    Baumann RP; Shyam K; Penketh PG; Remack JS; Brent TP; Sartorelli AC
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):288-95. PubMed ID: 14685775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation.
    Baumann RP; Seow HA; Shyam K; Penketh PG; Sartorelli AC
    Oncol Res; 2005; 15(6):313-25. PubMed ID: 16408696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine.
    Ishiguro K; Shyam K; Penketh PG; Sartorelli AC
    Mol Cancer Ther; 2005 Nov; 4(11):1755-63. PubMed ID: 16275997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU.
    Rice KP; Penketh PG; Shyam K; Sartorelli AC
    Biochem Pharmacol; 2005 May; 69(10):1463-72. PubMed ID: 15857610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine.
    Zhu R; Liu MC; Luo MZ; Penketh PG; Baumann RP; Shyam K; Sartorelli AC
    J Med Chem; 2011 Nov; 54(21):7720-8. PubMed ID: 21955333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KS900: A hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O(6)-alkylguanine-DNA alkyltransferase in neoplastic cells.
    Baumann RP; Ishiguro K; Penketh PG; Shyam K; Zhu R; Sartorelli AC
    Biochem Pharmacol; 2011 May; 81(10):1201-10. PubMed ID: 21396917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reductive activation of the prodrug 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119) selectively occurs in oxygen-deficient cells and overcomes O(6)-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance.
    Baumann RP; Penketh PG; Ishiguro K; Shyam K; Zhu YL; Sartorelli AC
    Biochem Pharmacol; 2010 Jun; 79(11):1553-61. PubMed ID: 20005211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and antitumor activity evaluation of a novel combi-nitrosourea prodrug: Designed to release a DNA cross-linking agent and an inhibitor of O(6)-alkylguanine-DNA alkyltransferase.
    Sun G; Zhang N; Zhao L; Fan T; Zhang S; Zhong R
    Bioorg Med Chem; 2016 May; 24(9):2097-107. PubMed ID: 27041398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formation of DNA interstrand cross-links by the novel chloroethylating agent 2-chloroethyl(methylsulfonyl)methanesulfonate: suppression by O6-alkylguanine-DNA alkyltransferase purified from human leukemic lymphoblasts.
    Brent TP; Lestrud SO; Smith DG; Remack JS
    Cancer Res; 1987 Jul; 47(13):3384-7. PubMed ID: 3034412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells.
    Zhu R; Baumann RP; Patridge E; Penketh PG; Shyam K; Ishiguro K; Sartorelli AC
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1853-9. PubMed ID: 23395657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
    Giles F; Verstovsek S; Thomas D; Gerson S; Cortes J; Faderl S; Ferrajoli A; Ravandi F; Kornblau S; Garcia-Manero G; Jabbour E; O'Brien S; Karsten V; Cahill A; Yee K; Albitar M; Sznol M; Kantarjian H
    Clin Cancer Res; 2005 Nov; 11(21):7817-24. PubMed ID: 16278404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine.
    Ishiguro K; Seow HA; Penketh PG; Shyam K; Sartorelli AC
    Mol Cancer Ther; 2006 Apr; 5(4):969-76. PubMed ID: 16648568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas.
    Penketh PG; Shyam K; Sartorelli AC
    Biochem Pharmacol; 2000 Feb; 59(3):283-91. PubMed ID: 10609557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. O6-alkylguanine-DNA alkyltransferase has opposing effects in modulating the genotoxicity of dibromomethane and bromomethyl acetate.
    Liu L; Williams KM; Guengerich FP; Pegg AE
    Chem Res Toxicol; 2004 Jun; 17(6):742-52. PubMed ID: 15206895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation and degradation of O(6)-alkylguanine-DNA alkyltransferase after reaction with nitric oxide.
    Liu L; Xu-Welliver M; Kanugula S; Pegg AE
    Cancer Res; 2002 Jun; 62(11):3037-43. PubMed ID: 12036910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models.
    Rapp M; Maurizis JC; Papon J; Labarre P; Wu TD; Croisy A; Guerquin-Kern JL; Madelmont JC; Mounetou E
    J Pharmacol Exp Ther; 2008 Jul; 326(1):171-7. PubMed ID: 18411412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pH-dependent general base catalyzed activation rather than isocyanate liberation may explain the superior anticancer efficacy of laromustine compared to related 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine prodrugs.
    Penketh PG; Finch RA; Sauro R; Baumann RP; Ratner ES; Shyam K
    Chem Biol Drug Des; 2018 Jan; 91(1):62-74. PubMed ID: 28636806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of 1-(3-deoxycytidyl),2-(1-deoxyguanosinyl)ethane cross-link formation in DNA by rat liver O6-alkylguanine-DNA alkyltransferase.
    Ludlum DB; Mehta JR; Tong WP
    Cancer Res; 1986 Jul; 46(7):3353-7. PubMed ID: 3708569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.
    Ishiguro K; Zhu YL; Shyam K; Penketh PG; Baumann RP; Sartorelli AC
    Biochem Pharmacol; 2010 Nov; 80(9):1317-25. PubMed ID: 20654586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.